Knob

Myriad Uranium Announces Addition of Highly Prospective Target Area Revealed by Historic Data Trove, Increases Wyoming Land Position by 41%

Retrieved on: 
Monday, February 26, 2024

The area is now part of the Copper Mountain Project, in which Myriad holds a 75% earnable interest.

Key Points: 
  • The area is now part of the Copper Mountain Project, in which Myriad holds a 75% earnable interest.
  • The identification and acquisition of the Knob claims is a result of Myriad's ongoing review of proprietary paper-based historical data sets.
  • The Knob target areas' mineralisation is understood to be in a flat-lying zone of fracturing within the host granite.
  • It is expected that the historical data trove will continue to allow Myriad to add high-potential prospects to the project.

Bispecific Antibodies: Structural Design, Production and Purification Strategies, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, November 22, 2023

TORONTO, Nov. 22, 2023 /PRNewswire-PRWeb/ -- Discover this groundbreaking webinar delving into the strategic approaches of bispecific antibody (BsAb) design, production and purification. BsAbs have become increasingly of interest by enabling new therapeutic applications for a variety of indications, including cancer, chronic inflammatory diseases, autoimmunity, neurodegeneration, bleeding disorders and infections. Currently, there are 12 bispecific antibodies approved worldwide.

Key Points: 
  • Attendees will learn the key considerations of bispecific antibody structural design and analysis of general design strategies.
  • The featured speaker will discuss production strategies and by-product purification plans for bispecific antibodies with different structures.
  • TORONTO, Nov. 22, 2023 /PRNewswire-PRWeb/ -- Discover this groundbreaking webinar delving into the strategic approaches of bispecific antibody (BsAb) design, production and purification.
  • Join this webinar to gain insights into the diverse applications, design considerations and production strategies of bispecific antibodies.

Microchip’s Detroit Automotive Technology Center is the Destination for Automotive Clients  

Retrieved on: 
Wednesday, October 18, 2023

Microchip Technology (Nasdaq: MCHP), a leading provider of smart, connected and secure embedded control solutions, today announces the expansion of its Detroit Automotive Technology Center in Novi, Michigan.

Key Points: 
  • Microchip Technology (Nasdaq: MCHP), a leading provider of smart, connected and secure embedded control solutions, today announces the expansion of its Detroit Automotive Technology Center in Novi, Michigan.
  • The 24,000-square-foot facility is the destination for automotive clients to explore new technologies and to meet with technical experts to get support for their end applications and designs.
  • Microchip has been part of the Detroit community since 1999, when it first opened its doors as an application and sales office.
  • “In addition to the Detroit location, we have Automotive Technology Centers in Munich, Shanghai, Tokyo and Austin, Texas, to support our global customer base.”
    “Microchip’s Automotive Technology Center demonstrates our commitment to the automotive industry by providing a destination for them to develop, test and refine applications in the design phase,” said Matthias Kaestner, corporate vice president of Microchip’s automotive business.

EL TESORO® TEQUILA ANNOUNCES NEWEST ADDITION TO THE MUNDIAL COLLECTION - EL TESORO® MUNDIAL: KNOB CREEK® RYE EDITION

Retrieved on: 
Monday, October 16, 2023

NEW YORK, Oct. 16, 2023 /PRNewswire/ -- El Tesoro de Don Felipe® Tequila, the award-winning Tequila producer from La Alteña Distillery in the Jalisco highlands of Mexico, and the third-generation Camarena distilling family, are proud to introduce the second installment of "The Mundial Collection" Limited Edition Cask Finishing Series: El Tesoro® Mundial: Knob Creek® Rye Edition. 

Key Points: 
  • The El Tesoro Mundial Collection represents a premium innovation and experimentation initiative for El Tesoro.
  • As a special one-time release, this is the first and only time El Tesoro® has been rested in Knob Creek Rye Barrels.
  • The Mundial series allows us to pursue these creative paths in tequila, and the Knob Creek® Rye edition is no different.
  • This year, El Tesoro® Mundial Collection: The Laphroaig Edition will be available alongside the El Tesoro® Mundial Collection: Knob Creek Rye Edition with updated premium gift packaging.

Biocytogen Officially Launches RenMice® Series

Retrieved on: 
Friday, September 15, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) officially announces the RenMice® series, which includes a collection of independently developed, fully human antibody mice and TCR mice with proprietary intellectual property.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) officially announces the RenMice® series, which includes a collection of independently developed, fully human antibody mice and TCR mice with proprietary intellectual property.
  • The RenMice® series encompasses five strains of fully human antibody/TCR mice: RenMab™, RenLite®, RenNano®, RenTCR™, and RenTCR-mimic™.
  • View the full release here: https://www.businesswire.com/news/home/20230915794363/en/
    RenMice Series and Their Drug Discovery Applications (Graphic: Business Wire)
    Since their successive release in 2019, Biocytogen’s RenMice series has received global recognition in the biopharmaceutical and biotechnology field.
  • As of June 30, 2023, Biocytogen has entered into RenMice licensing agreements with 20 biopharmaceutical/biotechnology companies worldwide; 42 target-nominated antibody development projects have been initiated.

Biocytogen Officially Launches RenMice® Series

Retrieved on: 
Friday, September 15, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) officially announces the RenMice® series, which includes a collection of independently developed, fully human antibody mice and TCR mice with proprietary intellectual property.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) officially announces the RenMice® series, which includes a collection of independently developed, fully human antibody mice and TCR mice with proprietary intellectual property.
  • The RenMice® series encompasses five strains of fully human antibody/TCR mice: RenMab™, RenLite®, RenNano®, RenTCR™, and RenTCR-mimic™.
  • View the full release here: https://www.businesswire.com/news/home/20230914583107/en/
    RenMice Series and Their Drug Discovery Applications (Graphic: Business Wire)
    Since their successive release in 2019, Biocytogen’s RenMice series has received global recognition in the biopharmaceutical and biotechnology field.
  • As of June 30, 2023, Biocytogen has entered into RenMice licensing agreements with 20 biopharmaceutical/biotechnology companies worldwide; 42 target-nominated antibody development projects have been initiated.

Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023

Retrieved on: 
Wednesday, August 9, 2023

Company recently announced license and collaboration expansions for next-gen multispecific antibodies for solid tumors with lead HER2/HER3 program, HSB-3215, in collaboration with OmniAb, Inc. and Minotaur Therapeutics, Inc.

Key Points: 
  • Company recently announced license and collaboration expansions for next-gen multispecific antibodies for solid tumors with lead HER2/HER3 program, HSB-3215, in collaboration with OmniAb, Inc. and Minotaur Therapeutics, Inc.
    BRIDGEWATER, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, today announced that it will be attending the Annual Sidoti Micro-Cap Virtual Conference being held on August 16-17, 2023.
  • “We’ve made a lot of progress since we’ve announced the strategic reprioritization of our drug pipeline making this an opportune time to share updates with the investment community,” says Randy Milby, CEO of Hillstream.
  • This will in turn complement Hillstream’s HSB-3215 program.
  • To schedule a meeting with the management team or view the presentation, please send an email to [email protected] or visit https://www.meetmax.com/sched/event_96493/investor_reg_new.html?attendee... .

Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215

Retrieved on: 
Thursday, July 20, 2023

BRIDGEWATER, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (“Hillstream”, the “Company”) today announced the expansion of its collaboration with Minotaur Therapeutics, Inc. (“Minotaur”) and its license agreement with OmniAb, Inc. (“OmniAb”) to advance the development of next generation targeted Knob biologics (PicobodiesTM) against HER3 and a new undisclosed oncology target. Hillstream will collaborate with Minotaur using OmniAb’s “OmniTaur™” technology to discover targeted biotherapeutic Picobodies complementing Hillstream’s most advanced program, HSB-3215, a HER2/HER3 bispecific antibody (BsAb).

Key Points: 
  • As a diverse group of molecules, BsAbs recognize distinct epitopes on two different antigens, in the case of HSB-3215, HER2 and HER3.
  • These validated targets, belong to the ERBB receptor tyrosine kinase family and are exploited by cancer cells to promote oncogenesis.
  • This conceivable “multi-specific” capacity of PicobodiesTM could more efficiently target multiple cell surface portions compared to known or existing biologics.
  • Hillstream is now poised to develop a novel technology for creating multiple proteins to enhance targeted cancer immunotherapy.”

Level Partners With Rejuvenation To Bring Invisible Smart Lock Technology To Timelessly Designed Door Sets

Retrieved on: 
Wednesday, May 10, 2023

Level Home Inc. , the company redefining the smart home experience, has teamed up with home goods brand Rejuvenation to equip its timelessly designed, customizable door sets with Level’s best-in-class, invisible smart home technology.

Key Points: 
  • Level Home Inc. , the company redefining the smart home experience, has teamed up with home goods brand Rejuvenation to equip its timelessly designed, customizable door sets with Level’s best-in-class, invisible smart home technology.
  • The lineup incorporates Level’s award-winning Level Bolt , the first and only invisible smart lock that installs on the inside of a door, to make Rejuvenation’s high-quality, exterior door sets smart, with zero sacrifice to design.
  • Adding to the line of more than 30 door sets that have been rolling out since January this year, Rejuvenation and Level are announcing five new collections today.
  • The new door sets will be available in Rejuvenation’s signature finishes – Aged Brass, Oil-Rubbed Bronze, and Polished Nickel:
    This press release features multimedia.

Andes and IAR Systems Together Enable Leading Vendor ILITEK to Accelerate the Development of its ISO 26262 Ready TDDI SoC ILI6600A

Retrieved on: 
Tuesday, February 14, 2023

The joint solution from Andes and IAR Systems is ISO 26262-certified with robust design methodology.

Key Points: 
  • The joint solution from Andes and IAR Systems is ISO 26262-certified with robust design methodology.
  • The LCD driver in ILI6600A supports up to 3 chips cascading and provides the number of colors up to 16.7M.
  • “The ILI6600A is our first ISO 26262 ASIL B ready product which provides robust, real-time and certified Fail detection functions.
  • The functional safety edition of IAR Embedded Workbench for RISC-V is certified by TÜV SÜD according to ten different standards, including ISO 26262.